| |
Decentralized clinical trials (DCTs) are redefining clinical research beyond the confines of traditional clinical trial sites. This recent shift presents immense promise for pediatric rare disease research – offering hope to patients and their families as they navigate the uncertainty of their diagnoses. Read our checklist to explore expert insights for the implementation of decentralized clinical trials in pediatric rare diseases. +(002)+120w.png)
|
|
Today’s Big NewsApr 15, 2024 |
| By Max Bayer Regeneron is joining its pharma peers, launching its own venture capital wing. The New York pharma plans to commit $100 million annually for the first five years. |
|
|
|
By James Waldron The FDA has placed a phase 1 trial of Neumora Therapeutics’ schizophrenia drug on hold after preclinical data revealed rabbits dosed with the drug had experienced convulsions. |
By Kevin Dunleavy 2023 was all about diabetes and obesity drug sellers Novo Nordisk and Eli Lilly posting huge revenue gains as they were the only companies in the biopharma industry with double-digit gains. At the other end of the spectrum, sellers of COVID products saw dramatic decreases in revenue as Pfizer, the top revenue drugmaker in 2022, had a 41% decrease, while Moderna and BioNTech tumbled out of the top 20. |
By Nick Paul Taylor Pulmocide has added new nuances to the chorus of evidence for its antifungal, reporting data from the phase 2 OPERA-S study to show the candidate can prevent and eradicate infections without causing the problems associated with existing therapies. |
|
Tuesday, April 23, 2024 | 2:00pm ET | 11:00am PT If you are embarking on the exciting journey of moving labs, this webinar is for you! Join us on April 23rd to learn from real-life stories the critical steps to a successful move and the common budget-draining mistakes to avoid. Register today! 
|
|
By James Waldron A year after a long-running clinical hold was lifted on MaaT Pharma’s pooled fecal therapy, the microbiome biotech has touted 18-month data as proof it’s on track to launch the drug in acute graft-versus-host disease in two years’ time. |
By Angus Liu After oncology experts reviewed arguments in favor of a surrogate endpoint to support multiple myeloma drug approvals, drug developers may soon have a new pathway in the R&D journey. |
By Gabrielle Masson Activist investor Shah Capital, which owns 6.7% of Novavax's stock, has claimed that the vaccine developer has been “historically mismanaged” as the firm tries to install new members onto the biotech's board. |
By Conor Hale Following last week’s de novo clearance for the AI program, Roche has stepped up to distribute Prenosis’ sepsis risk prediction tool through its diagnostic platforms. |
By Nick Paul Taylor AstraZeneca is sounding the crisis klaxon after spotting an “urgent and growing” global health situation that has “profound economic and environmental implications.” The drugmaker made the comments in response to forecasts of the impact of chronic kidney disease through 2032. |
By Heather Landi Health IT experts say the rift between the two companies exposes larger problems with health data exchange including a lack of transparency on who is accessing data and how it's being used along with the need for better gatekeeping. |
Fierce podcasts Don’t miss an episode |
| Using data from Fierce Biotech's layoff tracker, Gabrielle Masson and Max Bayer analyze the trends of layoffs in the first quarter of 2024, comparing them to previous years. |
|
|---|
|
|
|
Tuesday, April 30, 2024 | 2pm ET / 11am PT Liquid biopsies have shown tremendous progress for the early detection of cancer and for treatment monitoring, but still have limitations. The inclusion of protein glycosylation can help. Join usto learn more about the latest solutions for leveraging AI and machine learning to accelerate data processing, overcome current barriers, and provide crucial information. Register now. 
|
|
Whitepaper Antibody biomarkers are redefining precision medicine, from diagnosing diseases earlier to stratifying patients – download your FREE white paper today! Sponsored by: Sengenics Corporation LLC |
Whitepaper The use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
eBook Unlock the future of mAb manufacturing with our complete guide to integrating the revolutionary Gibco™ Efficient-Pro™ Medium and Feeds System, enhancing productivity and quality for exceptional outcomes Sponsored by: Thermo Fisher Scientific |
Whitepaper This paper assesses the current state of the oncology market, reviewing key expectations for 2024. It addresses CAR-T therapies, KRAS, radiopharmaceuticals, & targeted protein degradation. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Choosing the right contract lab can help drug developers accelerate their timelines and generate cost-efficiencies. For insights into what to look for when selecting a GMP/CMC lab partner read this white paper which delves into a range of factors that can support your needs in both the short-term and in planning for the future. Sponsored by: PPD®️ Laboratory Services |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
